key: cord-0764461-pkhinwlh
authors: Post, Nicoline F.; Luiten, Rosalie M.; Wolkerstorfer, Albert; Bekkenk, Marcel W.; Böhm, Markus
title: Does autoimmune vitiligo protect against COVID‐19 disease?
date: 2021-06-17
journal: Exp Dermatol
DOI: 10.1111/exd.14407
sha: e82c23d1be11dfb44575ae28a646b282479e0f6f
doc_id: 764461
cord_uid: pkhinwlh

The SARS‐CoV‐2 pandemic has evolved to a global health problem with a dramatic morbidity and mortality rate impacting our daily life and those of many patients. While there is evidence that some diseases are associated with an increased risk for development of a more severe course of COVID‐19, little is known on protective conditions. Importantly, clearance of viral infection and protection against disease manifestation crucially depends on functional innate and adaptive immunity and the interferon signalling axis. Here, we hypothesize that patients with non‐segmental vitiligo (NSV), an autoimmune skin (and mucosal) disorder, may clear SARS‐CoV‐2 infection more efficiently and have a lower risk of COVID‐19 development. Conversely, in case of COVID‐19 development, vitiligo autoimmunity may influence the cytokine storm‐related disease burden. In addition, immune activation during SARS‐CoV‐2 infection or COVID‐19 disease might increase vitiligo disease activity. Our hypothesis is based on the shift of the immune system in NSV towards adaptive type 1 (IFNγ and CD8 T cells) and innate immune responses. Identified susceptibility genes of NSV patients may further confer increased antiviral activity. To validate our hypothesis, we suggest an international consortium to perform a retrospective data registry and patient‐reported study on a large number of NSV patients worldwide during the COVID‐19 pandemic.

The SARS-CoV-2 pandemic has evolved to a global health problem with a dramatic morbidity and mortality rate impacting our daily life and those of many patients.

While there is evidence that some diseases are associated with an increased risk for development of a more severe course of COVID-19, little is known on protective conditions. Importantly, clearance of viral infection and protection against disease manifestation crucially depends on functional innate and adaptive immunity and the interferon signalling axis. Here, we hypothesize that patients with non-segmental vitiligo (NSV), an autoimmune skin (and mucosal) disorder, may clear SARS-CoV-2 infection more efficiently and have a lower risk of COVID-19 development. Conversely, in case of COVID-19 development, vitiligo autoimmunity may influence the cytokine storm-related disease burden. In addition, immune activation during SARS-CoV-2 infection or COVID-19 disease might increase vitiligo disease activity. Our hypothesis is based on the shift of the immune system in NSV towards adaptive type 1 (IFNγ and CD8 T cells) and innate immune responses. Identified susceptibility genes of NSV patients may further confer increased antiviral activity. To validate our hypothesis, we suggest an international consortium to perform a retrospective data registry and patient-reported study on a large number of NSV patients worldwide during the COVID-19 pandemic.

autoimmunity, coronavirus SARS-CoV-2, COVID-19, inflammation, vitiligo SNPs point to altered gene function that may predispose patients to autoimmunity but may also confer increased antiviral immunity.

Interestingly, NSV has been shown to protect against melanoma and non-melanoma skin cancer. 8, 9 The pathobiology of NSV involves adaptive type 1 immune responses with interferon (IFN)γ signalling and CD8 + T cells but also innate immune responses.

Both innate and adaptive immune pathways are important in clearing viral infections, by early innate responses of type I IFN and IFNγ producing NK cells, followed by adaptive immunity including IFNγ-producing T-cell responses and antiviral antibody response. 10, 11 Related corona viruses SARS-CoV and MERS-CoV are able to disrupt IFN signalling by Orf6 and Orf3b proteins, resulting in a delayed type I IFN response with loss of viral control during the early phase of infection. 12, 13 In SARS-CoV-2, these proteins are truncated with a diminished anti-IFN activity. Therefore, SARS-CoV-2 is more sensitive to IFN than related coronaviruses. 14 Interestingly, type I IFN treatment has been shown to decrease infection rate and viral replication of respiratory viruses. 15 The role of IFN in protection against SARS-CoV-2 infection is apparent in seriously ill COVID-19 patients with genetic defects of the type I IFN pathway. 16 Moreover, neutralizing autoantibodies that impair type I IFN immunity were found in 10.2% of the patients with life-threatening COVID-19 pneumonia, as compared to 0.33% of the patients with asymptomatic or mild symptoms of SARS-CoV-2 infection. 17 As compared to other respiratory viruses, SARS-CoV-2 induces an aberrant, less functional antiviral transcriptional response in infected cells, characterized by low type I and III IFN levels and high expression of chemokines and IL-6, which may drive COVID-19. 18 During the late phase of COVID-19 the production of type I and III IFN remained low, accompanied by increased production of inflammatory cytokines such as IL-6, IL-8 and TNFα. 18, 19 Moreover, IL-6 plasma levels were found higher in ICU patients compared to healthy subjects.

Other showed that IL-6 levels were significantly higher in patients with severe disease than in patients with mild disease, suggesting to be a predictive of mortality. 20 Further, lower systemic IFNγ levels were associated with lung fibrosis among COVID-19 patients. 21 The relationship of autoimmunity and COVID-19 has been described by COVID-19 disease characteristics that resemble autoimmune or autoinflammatory disorders, whereas the relative risk of autoimmune patients for COVID-19 is not known. 19, 22 To date, there are no data of patients with autoimmune thyroid disease, rheumatic diseases, systemic lupus or other autoimmune disorders being at higher risk of SAR-Cov-2 infection or more severe COVID-19 disease severity. [23] [24] [25] The relative susceptibility of patients with pre-existing autoimmunity to COVID-19 may be obscured by the potential benefit of immunosuppressive drugs, used in these patients, against COVID-19 disease development, or as COVID-19 treatment. In vitiligo, the absence of systemic immune suppressive treatment allows studying this relationship more specifically.

SARS-CoV infection is recognized by the immune system through viral protein that serve as a pathogen-associated molecular pattern (PAMP) by a TLR-related-TRAF3-independent mechanism. 26, 27 Furthermore, the infection triggers an inflammatory response characterized by increased production of interleukin IL-6, IFNγ and activation of NF-κB. 28 This MDA5-MAVS-NF-κB/IRF3 signalling pathway orchestrates the secretion of CXCL10 leading to CXCR3B activation and inducing apoptosis of melanocytes. 29 Moreover, vitiligo patients show an increased presence of NK and ILC1, cells that are more liable to respond to PAMPs. 30 

We propose an international consortium to perform a retrospective study in a large number of NSV patients worldwide during COVID-19 pandemic. To address the above questions, our concept includes a patient-reported study and a patient data registry study.

Employing a questionnaire study among NSV patients and controls (age between 16 and 55 years). Participating institutes will collect demographic patient data (age, gender, ethnicity, skin type) and data related to vitiligo disease activity, affected body surface area measured by the Self-Assessment Vitiligo Extent Score, medication questionnaires and previously developed vitiligo patient-reported outcome measures for vitiligo extent 32 and activity. 33 To analyse the relation between vitiligo and COVID-19 disease development risk and disease severity (questions 1 and 1a) , partners of patients or a best friend not suffering from vitiligo will be asked to fill out the same questionnaire (except for vitiligo-related questions) and thereby will serve as control group. Considering the infectiousness of SARS-CoV-2, chances are high partners, will be infected in case one of the two has been exposed to the virus. COVID-19 disease development and disease severity in vitiligo patients will be compared to the control group. This control group presumably matches well with regard to age, sex, skin type, ethnicity, social status and risk for SARS-CoV-2 infection. The patient and control groups analysed are confined to the age group between 16 and 55 years, to minimize the effect of increased risk in elderly and decreased risk in children on the analyses of this study. Since the history of autoimmune comorbidities of both vitiligo patients and controls is also collected, we can subsequently determine the effect of other frequently found autoimmune diseases on COVID-19 disease development and severity.

The effect of COVID-19 on vitiligo disease activity (question 2) will be analysed among vitiligo patients, in which vitiligo disease activity in vitiligo patients with COVID-19 will be compared to vitiligo patients without COVID-19. In case of increased vitiligo disease activity due to COVID-19, this will become apparent by the formation of new vitiligo lesions during the 3 months after COVID-19 disease suffering. The effect of COVID-19 on vitiligo could either be direct, due to increased immune activation, or indirect due to increased emotional stress of patients and resulting flares of increased vitiligo disease activity. To minimize the recall bias, the questionnaire will be conducted just after the summer.

In case all patient data registration is centralized in a national registry or health insurance registry, we will analyse (i) the vitiligo prevalence among patients with COVID-19 disease-related hospitalization or ICU admittance in 2020 as compared to non-COVID patient ICU data registered from 2000 until 2019 prior to the pandemic, as well as the prevalence of vitiligo in the general population, and (ii) the COVID-19 incidence among vitiligo patients as compared to the COVID-19 incidence in the general population. This more reliable analysis will strengthen the patient questionnaire study and will provide insight to what extent vitiligo is underrepresented in the COVID-19 patient population, when corrected for confounding factors (eg age, use of immune suppressive therapies). In these analyses, the gender distribution will also be analysed. Vitiligo generally occurs more equally in males and females 34,35 than most autoimmune disorders having an approximately 60/40 distribution for females/males. Based on this, these analyses will reveal whether the lower risk of COVID-19 disease development in females can be associated with vitiligo or another autoimmune disease. The relatively high prevalence (estimated 0.5%-2%) of vitiligo independent of sex or ethnicity is sufficiently comparable worldwide, 34, 35 to enable combining patient data across countries.

Our study may add a novel twist on the pathobiological (and evolutionary) role of NSV during viral infection. Validation of our concept may disclose new mechanistic and disease-interrelating insights into the pathophysiology of the SARS-CoV-2 pandemic.

None.

The authors declare no conflict of interest. 

WHO WHO Coronavirus WHO Coronavirus Disease/COVID-19

Presenting Characteristics, Comorbidities, and Outcomes Among 5700

Patients Hospitalized With COVID-19 in the New York City Area

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Immune-epidemiological parameters of the novel coronavirus -a perspective

Sex differences in immune responses

Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants

Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners

Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo

Long-term existence of SARS-Cov-2 in COVID-19 patients: Host immunity, viral virulence, and transmissibility

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Type 1 interferons as a potential treatment against COVID-19

Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice

SARS-CoV-2 is sensitive to type I interferon pretreatment

Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Autoinflammatory and autoimmune conditions at the crossroad of COVID-19

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Lower circulating interferon-gamma is a risk factor for lung fibrosis in COVID-19 patients

Covid-19 and autoimmunity

Managing rheumatoid arthritis during COVID-19

Thyroid disease in the time of COVID-19

Are patients with systemic lupus erythematosus at increased risk for COVID-19?

The membrane protein of severe acute respiratory syndrome coronavirus functions as a novel cytosolic pathogenassociated molecular pattern to promote beta interferon induction via a toll-like-receptor-related TRAF3-independent mechanism

Reading the viral signature by Toll-like receptors and other pattern recognition receptors

Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells

Targeting innate immunity to combat cutaneous stress: the vitiligo perspective

Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo

Core Outcome Set for clinical trials on Coronavirus Disease

Development and validation of a patient-reported outcome measure in vitiligo: the Self Assessment Vitiligo Extent Score (SA-VES)

Association of the Kobner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris

Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up

Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families